What Is Zentalis Pharmaceuticals, Inc. (ZNTL) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Zentalis Pharmaceuticals, Inc.'s intrinsic value is estimated at $2.35. Trading at its current price of $4.78, the valuation engine raises significant caution: 9 of 10 models flag downside risk, projecting an average implied return of -50.8%. Notably, PWERM sees the most upside at +1.3% (fair value: $4.84), while ML-RIV is the most conservative at -84.3% ($0.75). The spread between these extremes — +85.6% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About ZNTL?
10 of 13 models are currently active for ZNTL. Of these, 1 model suggests upside while 9 models suggest overvaluation. The Bayesian DCF estimates ZNTL's intrinsic value at $1.29, implying -72.9% downside from the current price. See which stocks rank higher →
How Does ZNTL Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, ZNTL ranks #196 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Zentalis Pharmaceuticals, Inc.'s positioning within the Pharmaceutical Preparations segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.
Is ZNTL a Value Trap?
CirclFi's Value Trap algorithm assigns ZNTL a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Zentalis Pharmaceuticals, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Zentalis Pharmaceuticals, Inc. earns a quality score of 5.1/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +85.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ZNTL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ZNTL's 10 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad